CW December 2004
Volume 13Issue Number 12 December 2004 ISSN 10593802 Higher Doses of Imatinib Lead to Stronger ResponsesImatinib (Gleevec) has become the treatment of choice for most patients with chronic myeloid leukemia (CML) at a standard dose of 400 mg daily. But pre-clinical and clinical observations suggest that higher doses may be more effective.
Go to Previous Page Go to Next Page Source & Additional Reading J. Cortes et al. Purchase Downloadable Full-text PDF of Article: $10.00 Subscription is more cost effective than purchasing PDFs on-the-fly. Click here for details. Download Complete Issue CW December 2004Purchase Downloadable Full-text PDF of Complete Issue: $20.00 |
|
Member Login | Home | Offices | Subscribe | Glossary | Cancer Technologies | Contact Us
Adenine Press, 2066 Central Avenue, Schenectady, NY 12304 USA |
Re-initialize IP-based Login |
